RESUMO
Objetivou-se avaliar o efeito da classe de tamanho de leitegada ao nascer sobre a variação do peso ao nascer e ao desmame e sobre a taxa de sobrevivência dos leitões do nascimento ao desmame. Para isso usou-se informações de peso individual ao nascer e ao desmame de leitões de um banco de dados de 295 leitegadas de suínos da raça Landrace, nascidos entre 2000 e 2010, em uma granja de suínos do oeste do estado do Paraná. As leitegadas foram classificadas pelo número total de leitões nascidos em pequenas (até 7 leitões), médias (8 a 13 leitões) e grandes (14 e mais leitões). Os dados foram analisados considerando-se os efeitos de ano de acasalamento das porcas e classe de tamanho de leitegada ao nascer. Correlações entre as características de peso médio e variância do peso e tamanho da leitegada foram maiores nas leitegadas médias e grandes. Classe de tamanho da leitegada influenciou significativamente peso médio ao nascer e ao desmame dos leitões e variância do peso ao nascer. Leitões de leitegadas médias e grandes pesaram menos, apresentaram maior variação do peso ao nascer e menor taxa de sobrevivência até o desmame do que leitões de leitegadas pequenas...
The objective of this study was to evaluate the effect of the size class of the litter at birth on the variation in birth and weaning weights and on the survival rate of piglets from birth to weaning. For this purpose, records of individual weight at birth and weaning of piglets obtained from a database of 295 Landrace litters born between 2000 and 2010 on a pig farm in the western region of the State of Paraná were used. The litters were classified as small (up to 7 piglets), medium (8 to 13 piglets), and large (> 14 piglets) according to the total number of piglets born. The data were analyzed considering the effects of the year of sow mating and size class of the litter at birth. The correlations between mean weight and variance in litter weight and size were higher for medium and large litters. The size class of the litter significantly influenced the mean weight of piglets at birth and weaning and the variance in birth weight. Piglets born in medium and large litters weighed less and exhibited greater birth weight variation and a lower survival rate until weaning than piglets born in small litters...
Assuntos
Animais , Crescimento e Desenvolvimento , Desmame , Peso ao Nascer , Taxa de Sobrevida , SuínosRESUMO
Objetivou-se avaliar o efeito da classe de tamanho de leitegada ao nascer sobre a variação do peso ao nascer e ao desmame e sobre a taxa de sobrevivência dos leitões do nascimento ao desmame. Para isso usou-se informações de peso individual ao nascer e ao desmame de leitões de um banco de dados de 295 leitegadas de suínos da raça Landrace, nascidos entre 2000 e 2010, em uma granja de suínos do oeste do estado do Paraná. As leitegadas foram classificadas pelo número total de leitões nascidos em pequenas (até 7 leitões), médias (8 a 13 leitões) e grandes (14 e mais leitões). Os dados foram analisados considerando-se os efeitos de ano de acasalamento das porcas e classe de tamanho de leitegada ao nascer. Correlações entre as características de peso médio e variância do peso e tamanho da leitegada foram maiores nas leitegadas médias e grandes. Classe de tamanho da leitegada influenciou significativamente peso médio ao nascer e ao desmame dos leitões e variância do peso ao nascer. Leitões de leitegadas médias e grandes pesaram menos, apresentaram maior variação do peso ao nascer e menor taxa de sobrevivência até o desmame do que leitões de leitegadas pequenas...(AU)
The objective of this study was to evaluate the effect of the size class of the litter at birth on the variation in birth and weaning weights and on the survival rate of piglets from birth to weaning. For this purpose, records of individual weight at birth and weaning of piglets obtained from a database of 295 Landrace litters born between 2000 and 2010 on a pig farm in the western region of the State of Paraná were used. The litters were classified as small (up to 7 piglets), medium (8 to 13 piglets), and large (> 14 piglets) according to the total number of piglets born. The data were analyzed considering the effects of the year of sow mating and size class of the litter at birth. The correlations between mean weight and variance in litter weight and size were higher for medium and large litters. The size class of the litter significantly influenced the mean weight of piglets at birth and weaning and the variance in birth weight. Piglets born in medium and large litters weighed less and exhibited greater birth weight variation and a lower survival rate until weaning than piglets born in small litters...(AU)
Assuntos
Animais , Peso ao Nascer , Desmame , Taxa de Sobrevida , Crescimento e Desenvolvimento , SuínosRESUMO
The objective of this multicenter prospective study was to determine the clinical efficacy and toxicity of a polychemotherapeutic third generation regimen, VACOP-B, with or without radiotherapy as front-line therapy in aggressive localized non-Hodgkin's lymphoma. Ninety-three adult patients (47 males and 46 females, median age 45 years) with aggressive localized non-Hodgkin's lymphoma, 43 in stage I and 50 in stage II (non-bulky), were included in the study. Stage I patients received VACOP-B for 6 weeks plus involved field radiotherapy and stage II patients received 12 weeks VACOP-B plus involved field radiotherapy on residual masses. Eighty-six (92.5 percent) achieved complete remission and 4 (4.3 percent) partial remission. Three patients (3.2 percent) were primarily resistant. Ten-year probability of survival, progression-free survival and disease-free survival were 87.3, 79.9 and 83.9 percent, respectively. Eighty-four patients are surviving at a median observation time of 57 months (range: 6-126). Statistical analysis showed no difference between stages I and II in terms of response, ten-year probability of survival, progression-free survival or disease-free survival. Side effects and toxicity were negligible and were similar in the two patient groups. The results of this prospective study suggest that 6 weeks of VACOP-B treatment plus radiotherapy may be the therapy of choice in stage I aggressive non-Hodgkin's lymphoma. Twelve weeks of VACOP-B treatment with or without radiotherapy was shown to be effective and feasible for stage II. These observations need to be confirmed by a phase III study comparing first and third generation protocols in stage I-II aggressive non-Hodgkin's lymphoma.
Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Pessoa de Meia-Idade , Linfoma não Hodgkin , Itália , Estadiamento de Neoplasias , Estudos Prospectivos , Radioterapia Adjuvante , Análise de Sobrevida , Resultado do TratamentoRESUMO
The objective of this multicenter prospective study was to determine the clinical efficacy and toxicity of a polychemotherapeutic third generation regimen, VACOP-B, with or without radiotherapy as front-line therapy in aggressive localized non-Hodgkin's lymphoma. Ninety-three adult patients (47 males and 46 females, median age 45 years) with aggressive localized non-Hodgkin's lymphoma, 43 in stage I and 50 in stage II (non-bulky), were included in the study. Stage I patients received VACOP-B for 6 weeks plus involved field radiotherapy and stage II patients received 12 weeks VACOP-B plus involved field radiotherapy on residual masses. Eighty-six (92.5%) achieved complete remission and 4 (4.3%) partial remission. Three patients (3.2%) were primarily resistant. Ten-year probability of survival, progression-free survival and disease-free survival were 87.3, 79.9 and 83.9%, respectively. Eighty-four patients are surviving at a median observation time of 57 months (range: 6-126). Statistical analysis showed no difference between stages I and II in terms of response, ten-year probability of survival, progression-free survival or disease-free survival. Side effects and toxicity were negligible and were similar in the two patient groups. The results of this prospective study suggest that 6 weeks of VACOP-B treatment plus radiotherapy may be the therapy of choice in stage I aggressive non-Hodgkin's lymphoma. Twelve weeks of VACOP-B treatment with or without radiotherapy was shown to be effective and feasible for stage II. These observations need to be confirmed by a phase III study comparing first and third generation protocols in stage I-II aggressive non-Hodgkin's lymphoma.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Linfoma não Hodgkin/tratamento farmacológico , Adolescente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Bleomicina/administração & dosagem , Bleomicina/efeitos adversos , Ciclofosfamida/administração & dosagem , Ciclofosfamida/efeitos adversos , Doxorrubicina/administração & dosagem , Doxorrubicina/efeitos adversos , Etoposídeo/administração & dosagem , Etoposídeo/efeitos adversos , Feminino , Humanos , Itália , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Prednisona/administração & dosagem , Prednisona/efeitos adversos , Estudos Prospectivos , Radioterapia Adjuvante , Análise de Sobrevida , Resultado do Tratamento , Vincristina/administração & dosagem , Vincristina/efeitos adversosRESUMO
O transplante autólogo de célula progenitora ou medula óssea (ATMO) tem demonstrado capacidade de superar resistência tumoral através da elevação da intensidade de dose de drogas disponíveis e radioterapia. ATMO foi inicialmente utilizado em LNH após recidiva em primeira linha ou refratários. ATMO tem demonstrado maior utilidade em condições clínicas mais favoráveis como na remissão parcial (RP), primeira remissão completa (RC) e como primeira linha após quimioterapia. Quimioterapia de alta dose e ATMO se tornaram a terapêutica standard para pacientes elegíveis com LNH agressivo, recorrente e quimiosensível. Pacientes primariamente refratários e com recidiva resistente não são boas indicações e devem ser considerados como grupo elegível para estudos de fase II. Talvez, haja um papel do ATMO em pacientes parcialmente responsivos. Entretanto, novos e grandes estudos randomizados são necessários para esclarecer esta questão. Um desafio para o manuseio dos linfomas é a definição da terapia de alta dose seguida do ATMO como terapêutica inicial para os LNH agressivos, identificando pacientes que não possam ser curados com terapêutica convencional. Uma série de estudos retrospectivos ou controlados parece indicar os chamados pacientes de "alto-risco", definido pela IPI como potencial alvo destas terapêuticas intensificadas. Entretanto, de acordo com dados publicados, o problema permanece aberto para debates. Estudos grandes e randomizados são necessários e bem vindos e devem ser considerados prioridade neste campo da ciência médica.
Assuntos
Transplante Autólogo , Terapêutica , Medula Óssea , Linfoma não Hodgkin , Transplante de Células-Tronco , Tratamento Farmacológico , LinfomaRESUMO
OBJECTIVE: We analysed peripheral blood progenitor cell (PBPC) mobilisation and collection in order to assess the main factors related to CD34(+) cell yields in patients affected by haematological malignancies. PATIENTS AND METHODS: The features of CD34(+) cell mobilisation of patients with haematological malignancies that underwent autologous bone marrow transplantation were examined. Mobilisation chemotherapy consisted mainly of cyclophosphamide (CY) 4 or 7 g/m(2) followed by growth factors. Leukapheresis was started when the WBC counts reached 1.0x10(9)/l with the aim to collect at least 5x10(6) CD34(+) cells/kg body weight. The aphereses were performed on continuous-flow blood cell separators. The analysed variables were: age, diagnosis, CT mobilisation regimen, type of growth factor, number of previous CT lines, prior radiotherapy, days for WBC recovery and number of aphereses procedures to achieve the target of CD34(+) cells. RESULTS: There were 41 consecutive patients (26 M/15 F): 21 non-Hodgkin's lymphoma (NHL), 15 Hodgkin's disease (HD), two chronic myeloid leukaemia (CML) and three multiple myeloma (MM). Eleven patients could not collect the proposed threshold of CD34(+) cells. CY 4 mobilised patients recovered WBC counts in less days (P=0.03). By ANOVA, the days to WBC recovery had a linear function of the predictors "number of aphereses" and "type of mobilisation CT" (coefficients: 0.86 and 0.95, respectively). For the number of aphereses and WBC recovery after CT mobilisation, we obtained a correlation coefficient of 0.36 (P=0.02). CONCLUSION: This study shows that it is feasible to mobilise and collect PBPC in patients previously treated with CT with or without RT. There was a linear correlation between the days for WBC recovery and the number of aphereses needed to collect the target number of CD34(+) cells. The study suggests that early WBC recovery, using mainly CY 4 mobilisation chemotherapy, is an important predictor of a low number of aphereses to achieve a good CD34(+) yield.
Assuntos
Contagem de Células Sanguíneas , Neoplasias Hematológicas/sangue , Mobilização de Células-Tronco Hematopoéticas , Leucaférese , Adolescente , Adulto , Antígenos CD34/análise , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Caspase 14 , Caspases/administração & dosagem , Criança , Cisplatino/administração & dosagem , Terapia Combinada , Ciclofosfamida/farmacologia , Citarabina/administração & dosagem , Dexametasona/administração & dosagem , Etoposídeo/administração & dosagem , Estudos de Viabilidade , Feminino , Fator Estimulador de Colônias de Granulócitos/farmacologia , Fator Estimulador de Colônias de Granulócitos e Macrófagos/farmacologia , Neoplasias Hematológicas/tratamento farmacológico , Neoplasias Hematológicas/terapia , Células-Tronco Hematopoéticas , Humanos , Controle de Infecções , Contagem de Leucócitos , Leucócitos Mononucleares , Masculino , Pessoa de Meia-Idade , Proteínas Recombinantes/farmacologia , Fatores de TempoRESUMO
Clinical trials indicate that amifostine may confer protection on various normal tissues without attenuating anti-tumor response. When administered prior to chemotherapy or radiotherapy, it may provide a broad spectrum of cytoprotection including against alkylating drugs. The mechanism of protection resides in the metabolism at normal tissue site by membrane-bound alkaline phosphatase. Toxicity of this drug is moderate with hypotension, nausea and vomiting, and hypocalcemia being observed. We report a phase II study using amifostine as a protective drug against high-dose cyclophosphamide (HDCY) (7 g/m2), used to mobilize peripheral blood progenitor cells (PBPC) and to reduce tumor burden. We enrolled 29 patients, 22 (75. 9%) affected by aggressive and 7 (24.1%) by indolent non-Hodgkin's lymphoma (NHL), who were submitted to 58 infusions of amifostine and compared them with a historical group (33 patients) affected by aggressive NHL and treated with VACOP-B followed by HDCY. The most important results in favor of amifostine were the reduction of intensity of cardiac, pulmonary and hepatic toxicity, and a significant reduction of frequency and severity of mucositis (P = 0. 04). None of the 29 patients died in the protected group, while in the historical group 2/33 patients died because of cardiac or pulmonary toxicity and 2 patients stopped therapy due to toxicity. Amifostine did not prevent the aplastic phase following HDCY. PBPC collection and hematological recovery were adequate in both groups. The number of CFU-GM (colony-forming units-granulocyte/macrophage) colonies and mononuclear cells in the apheresis products was significantly higher in the amifostine group (P = 0.02 and 0.01, respectively). Side effects were mild and easily controlled. We conclude that amifostine protection should be useful in HDCY to protect normal tissues, with acceptable side effects.
Assuntos
Amifostina/farmacologia , Antineoplásicos Alquilantes/administração & dosagem , Ciclofosfamida/administração & dosagem , Citoproteção , Linfoma não Hodgkin/tratamento farmacológico , Protetores contra Radiação/uso terapêutico , Adolescente , Adulto , Amifostina/efeitos adversos , Antineoplásicos Alquilantes/efeitos adversos , Ciclofosfamida/efeitos adversos , Citoproteção/efeitos dos fármacos , Estudos de Viabilidade , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Protetores contra Radiação/efeitos adversos , Estatísticas não Paramétricas , Resultado do TratamentoRESUMO
Clinical trials indicate that amifostine may confer protection on various normal tissues without attenuating anti-tumor response. When administered prior to chemotherapy or radiotherapy, it may provide a broad spectrum of cytoprotection including against alkylating drugs. The mechanism of protection resides in the metabolism at normal tissue site by membrane-bound alkaline phosphatase. Toxicity of this drug is moderate with hypotension, nausea and vomiting, and hypocalcemia being observed. We report a phase II study using amifostine as a protective drug against high-dose cyclophosphamide (HDCY) (7 g/m2), used to mobilize peripheral blood progenitor cells (PBPC) and to reduce tumor burden. We enrolled 29 patients, 22 (75.9 percent) affected by aggressive and 7 (24.1 percent) by indolent non-Hodgkin's lymphoma (NHL), who were submitted to 58 infusions of amifostine and compared them with a historical group (33 patients) affected by aggressive NHL and treated with VACOP-B followed by HDCY. The most important results in favor of amifostine were the reduction of intensity of cardiac, pulmonary and hepatic toxicity, and a significant reduction of frequency and severity of mucositis (P = 0.04). None of the 29 patients died in the protected group, while in the historical group 2/33 patients died because of cardiac or pulmonary toxicity and 2 patients stopped therapy due to toxicity. Amifostine did not prevent the aplastic phase following HDCY. PBPC collection and hematological recovery were adequate in both groups. The number of CFU-GM (colony-forming units-granulocyte/macrophage) colonies and mononuclear cells in the apheresis products was significantly higher in the amifostine group (P = 0.02 and 0.01, respectively). Side effects were mild and easily controlled. We conclude that amifostine protection should be useful in HDCY to protect normal tissues, with acceptable side effects.
Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Pessoa de Meia-Idade , Amifostina/farmacologia , Antineoplásicos Alquilantes/uso terapêutico , Ciclofosfamida/uso terapêutico , Citoproteção , Linfoma não Hodgkin/tratamento farmacológico , Protetores contra Radiação/farmacologia , Amifostina/toxicidade , Antineoplásicos Alquilantes/administração & dosagem , Ciclofosfamida/administração & dosagem , Citoproteção/efeitos dos fármacos , Estudos de Viabilidade , Protetores contra Radiação/toxicidade , Estatísticas não Paramétricas , Resultado do TratamentoRESUMO
Abdominal aortic aneurysms (AAA) usually undergo progressive dilatation and eventually may rupture,complication that caries a high mortality rate. If certain clinical conditions, like operative risk and aortic diameter are met, all patients should be considered for surgical repair. Analysis of our results with the surgical treatment of asymptomatic AAA prompted this stydy. Our of 479 consecutive patients operated because of AAA between 1976 and 1995, 378 (79 percent) were electively treated. Two decades: 1976-85 (101 patients) and 1986-95 (277 patients) were compared as far as associated medical conditions, surgical procedures, complications and mortality rate. There was no difference in age, sex, risk factors and aortic diameter. During the second decade we favoured the use of aortic tube grafts (53 percent vs 25 percent, p < 0.01) and epidural anesthesia (95 percent vs 35 percent, p < 0.01). During the last decade only 53.3 percent of the patients received blood transfusion, compared to 95.3 percent during the first period (p < 0.001). Operative mortality decreased from 5.94 percent to 0.72 percent (p < 0.05). Postoperative hospital stay diminished from 11.2 ñ 8.2 to 9.6 ñ 6.3 days (p < 0.05). These results compare favourable with those reported from other academic centers and support our therapeutic approach. Our contemporary surgical results serve as a reference for future clinical evaluation of endovascular procedures currently under investigation
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Aneurisma da Aorta Abdominal/cirurgia , Complicações Pós-Operatórias/epidemiologia , Cirurgia Torácica , Procedimentos Cirúrgicos Eletivos/estatística & dados numéricos , Anestesia , Aneurisma da Aorta Abdominal/complicaçõesRESUMO
Una mujer de 56 años posterior a una histerectomía por leimiomatosis atípica, debuta con metástasis pulmonares de un leimiosarcoma, sin evidencias de otro foco primario que el uterino. Realizamos una revisión y discusión del tema, motivados por la rara forma de presentación y evolución de la lesión maligna